Hariprasad Vankayalapati

Author

Huntsman Cancer Institute ORCID

Also Known As

H Vankayalapati, H. Vankayalapati, HARIPRASAD VANKAYALAPATI, Hariprasad Vankayalapati, Vankayalapati, Hariprasad

126

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Huntsman Cancer Institute University of Utah University of Arizona City of Hope SuperGen (United States)

About

Hariprasad Vankayalapati is an author at Huntsman Cancer Institute specializing in medicine, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.3K
2	Natural Sciences	10	10	983
3	Biochemistry	9	9	907
4	Cell Biology	7	7	579
5	Biomolecular Engineering	1	1	89

Hariprasad Vankayalapati

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Telomestatin, a Potent Telomerase Inhibitor That Interacts Quite Specifically with the Human Telomeric Intramolecular G-Quadruplex Mu-Yong Kim, Hariprasad Vankayalapati, Kazuo Shin‐ya, Journal of the American Chemical Society	2002	512
Design and Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex Structure Jeyaprakashnarayanan Seenisamy, Bashyam Sridevi, Vijay Gokhale, Journal of the American Chemical Society Combinatorial ChemistryCationic PorphyrinsMolecular BiologyOrganic ChemistryC-myc Promoter	2005	315
High-Throughput Virtual Screening Identifies Novel <i>N</i>′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors Venkataswamy Sorna, Emily R. Theisen, Bret J. Stephens, Journal of Medicinal Chemistry Drug TargetHit IdentificationHistone Lysine MethylationCompound LibraryReversible Lsd1 Inhibitors	2013	205
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma Felipe Lorenzo, Chunzhang Yang, Mark Ng Tang Fui, Journal of Molecular Medicine Somatic VariantCongenital PolycythemiaGenetic DisorderGeneticsPathology	2012	173
S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor <i>In vivo</i> and Can Reduce Tumor Growth Jody C. Chuang, Steven L. Warner, David Vollmer, Molecular Cancer Therapeutics	2010	151
Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. Wenhu Duan, Anupama Rangan, Hariprasad Vankayalapati, PubMed Bioorganic ChemistryMolecular BiologyOrganic ChemistryHeterocycle ChemistryChemical Biology	2001	107
Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors Alexis Mollard, Steven L. Warner, Lee T. Call, ACS Medicinal Chemistry Letters Catalytic DomainDrug TargetPharmacotherapyChemical BiologyMedicinal Chemistry	2011	89
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer Raffaella Soldi, Tithi Ghosh, Alexis Weston, PLoS ONE Molecular BiologyAnti-tumor ImmunityCancer BiologyEpigeneticsTumor Biology	2020	80
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Emmanuelle J. Meuillet, Daruka Mahadevan, Hariprasad Vankayalapati, PubMed Dpi 1-Molecular RegulationApoptosisMolecular BiologyCell Death	2003	78
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel Jinhua Zhou, Albandri Alfraidi, Shu Zhang, Clinical Cancer Research	2016	70

Page 1